Lesson plan
Custirsen
Custirsen (also known as OGX-011 and CC-8490), usually supplied as its sodium salt, is an investigational drug that is under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving overall survival. Custirsen was developed through a collaboration between OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. agreed to develop and commercialize custirsen.
Article summary
Custirsen (also known as OGX-011 and CC-8490), usually supplied as its sodium salt, is an investigational drug that is under clinical testing for the treatment of cancer. It is an antisense oligonucleotide (ASO) targeting clusterin expression. In metastatic prostate cancer, custirsen showed no benefit in improving overall survival. Custirsen was developed through a collaboration between OncoGenex Pharmaceuticals Inc. and Isis. In 2009, OncoGenex Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. agreed to develop and commercialize custirsen.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.